RGEN Quote, Financials, Valuation and Earnings

ICU Medical has a net margin of 3.45% compared to Repligen's net margin of -2.56%. Repligen's return on equity of -1.16% beat ICU Medical's return on equity of -4.64%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 51.12%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 44.94%. Given that Repligen has higher upside potential than ICU Medical, analysts believe Repligen is more attractive than ICU Medical.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are smaller than ICU Medical quarterly revenues of $604.7M. Repligen's net income of $5.8M is higher than ICU Medical's net income of -$15.5M. Notably, Repligen's price-to-earnings ratio is 633.44x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.48x versus 1.30x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

908 Devices has a net margin of 3.45% compared to Repligen's net margin of -103.33%. Repligen's return on equity of -1.16% beat 908 Devices's return on equity of -12.31%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 51.12%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could fall by -7.72%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than 908 Devices quarterly revenues of $11.8M. Repligen's net income of $5.8M is lower than 908 Devices's net income of $43.6M. Notably, Repligen's price-to-earnings ratio is 633.44x while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.48x versus 3.37x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

UFP Technologies has a net margin of 3.45% compared to Repligen's net margin of 11.6%. Repligen's return on equity of -1.16% beat UFP Technologies's return on equity of 19.38%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 51.12%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 35.84%. Given that Repligen has higher upside potential than UFP Technologies, analysts believe Repligen is more attractive than UFP Technologies.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.979%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than UFP Technologies quarterly revenues of $148.1M. Repligen's net income of $5.8M is lower than UFP Technologies's net income of $17.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while UFP Technologies's PE ratio is 28.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.48x versus 3.26x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 3.45% compared to Repligen's net margin of 0.18%. Repligen's return on equity of -1.16% beat Xtant Medical Holdings's return on equity of -26.62%.

Repligen has a consensus price target of $183.13, signalling upside risk potential of 51.12%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 147.18%. Given that Xtant Medical Holdings has higher upside potential than Repligen, analysts believe Xtant Medical Holdings is more attractive than Repligen.

Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Repligen's net income of $5.8M is higher than Xtant Medical Holdings's net income of $58K. Notably, Repligen's price-to-earnings ratio is 633.44x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.48x versus 0.79x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.